| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.7 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | Bosutinib | FIMM | pan-cancer | AAC | -0.14 | 0.7 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.7 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |